Compare Sana Biotechnology Inc (SANA) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Tesla, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Tesla, Inc. trades at $327.33 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 1159.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| SANA | TSLA | |
|---|---|---|
Market Cap | $1.13B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $489.88 |
52-Week Low | $2.68 | $298.16 |
Enterprise Value | $1.05B | $1.29T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Tesla (TSLA) trades at $326.95, down 1.18% on the day, amid a bearish technical signal and mixed fundamentals. The stock faces pressure from a recent earnings miss in Q2 2026 but maintains strong operating cash flow of $14.75B in 2025. Recent news highlights regulatory approval for its driver-assistance software in Europe (Reuters, 2026-04-10) and a surge in German registrations, though competition and valuation concerns persist.
Outlook remains bifurcated: long-term growth hinges on AI and autonomy execution, but near-term risks include high P/E of 308.16 and softening auto demand. Analyst consensus price target of $393.87 suggests upside potential if innovation milestones are met, yet investor patience is required amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
